The short version of incretin fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-01-27 and is reviewed periodically as new material appears.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, with mass confirmation by electrospray ionisation mass spectrometry. Peptide mapping after enzymatic digestion verifies the primary sequence. Size-exclusion chromatography quantifies aggregates, while circular dichroism provides a secondary-structure fingerprint. Bioanalytical quantification in plasma uses immunoassay or LC-MS/MS. Reported purity for research-grade lots is commonly 95 percent or higher, and residual water content is checked by Karl Fischer titration.
As a peptide, tirzepatide is handled as a lyophilised solid in research settings and as a preserved solution in finished products. Aqueous solubility is pH dependent and reaches a minimum near the isoelectric point, which lies close to pH 5.4. Stock solutions are typically prepared in neutral or slightly basic buffer to limit precipitation. The solid is hygroscopic and should be equilibrated to room temperature before opening so that condensation does not form on the powder surface.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Dual incretin receptor agonist |
| Amino acid count | 39 residues | Includes non-natural residues |
| Approximate mass | 4.8 kDa | Reported values vary slightly by source |
| Fatty acid component | C20 diacid | Supports albumin binding |
| First US approval | 2022 | Glycemic indication, weight management followed |
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Research-grade material circulates through suppliers that differ widely in documentation and testing practice, so a certificate of analysis is a starting point rather than proof of quality. Independent verification typically repeats chromatographic purity and mass confirmation on the received lot, and compares results against a retained reference standard. Regulatory status varies by jurisdiction, and a substance cleared as a medicine is not interchangeable with a research chemical of the same name. Open questions include how closely non-pharmaceutical lots match approved material in impurity profile and in aggregate content.
Solid tirzepatide is handled as a lyophilised, hygroscopic peptide powder that should be kept desiccated, protected from light, and stored frozen, typically at or below minus twenty degrees Celsius for long-term retention. Material left at ambient temperature for extended periods can take up moisture, which promotes aggregation and deamidation. Commercial liquid presentations are kept refrigerated between two and eight degrees Celsius and are not frozen. Reconstituted laboratory solutions are generally held cold and used within a short window because hydrolysis and oxidation continue slowly in solution.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
In Palestine, internationalisation was proposed, with the form of administration to be confirmed after consultation with both Russia and Hussein; the January draft noted Christian and Muslim interests, and that "members of the Jewish community throughout the world have a conscientious and sentimental interest in the future of the country." Prior to this point, no active negotiations with Zionists had taken place, but Sykes had been aware of Zionism, was in contact with Moses Gaster – a former President of the English Zionist Federation – and may have seen Samuel's 1915 memorandum. On 3 March, while Sykes and Picot were still in Petrograd, Lucien Wolf (secretary of the Foreign Conjoint Committee, set up by Jewish organizations to further the interests of foreign Jews) submitted to the Foreign Office, the draft of an assurance (formula) that could be issued by the allies in support of Jewish aspirations:
=== Terminal transferases === Terminal transferases are transferases that can be used to label DNA or to produce plasmid vectors. It accomplishes both of these tasks by adding deoxynucleotides in the form of a template to the downstream end or 3' end of an existing DNA molecule. Terminal transferase is one of the few DNA polymerases that can function without an RNA primer.
==== Cotranslational folding ==== The ribosome is known to actively participate in the protein folding. The structures obtained in this way are usually identical to the ones obtained during protein chemical refolding; however, the pathways leading to the final product may be different. In some cases, the ribosome is crucial in obtaining the functional protein form. For example, one of the possible mechanisms of folding of the deeply knotted proteins relies on the ribosome pushing the chain through the attached loop.
In the early 17th century, the majority of the labour in Barbados was provided by European indentured servants, mainly English, Irish and Scottish, with African and native American slaves providing little of the workforce. The introduction of sugar cane in 1640 completely transformed society and the economy. Barbados eventually had one of the world's largest sugar industries. The workable sugar plantation required a large investment and a great deal of heavy labour. At first, Dutch traders supplied the equipment, financing, and African slaves, in addition to transporting most of the sugar to Europe. In 1644, the population of Barbados was estimated at 30,000, of which about 800 were of African descent, with the remainder mainly of English descent. By 1700, there were 15,000 free whites and 50,000 enslaved Africans. In Jamaica, although the African slave population in the 1670s and 1680s never exceeded 10,000, by 1800 it had increased to over 300,000. The increased implementation of slave codes or black codes, which created differential treatment between Africans and the white workers and ruling planter class. In response to these codes, several slave rebellions were attempted or planned during this time, but none succeeded.
Catholic Benevolent Legion Catholic Daughters of the Americas Catholic Family Life Insurance - Founded August 1868 by John Martin Henni, the first Archbishop of Milwaukee, as the Family Protective Association. Incorporated in March 1869. Claims to be the oldest Catholic fraternal order, the first to adopt the legal reserve system, first to insure women and children, and first to provide Masses for living and deceased members. Changed name to Catholic Family Life Insurance in 1949. Had 37,000 members in 1967, 47,000 in 54 branches in 1979, 45,000 in 78 branches in 2010. Open to all members of the Catholic faith who were over 18. Headquarters in Milwaukee. Locals called Branches, of which there were 54 in 1979. The national convention is the "Supreme Governing Body", which meets every four years. Sponsors home and foreign missions; invests and makes loans to the building of churches and Catholic schools, hospitals (apparently not loans), a "respect for life" campaign against abortion; and also includes concern for aged and handicapped. Supports many charities such as the "Catholic Rural Life" movement for family farms, Cancer Fund, Heart Fund, Red Cross, and Community Chest. Also sponsors summer camps, social dances, athletic events, family campouts, picnics, and teen parties. Merged with Union Saint-Jean-Baptiste in 1991. Merged with Northern Fraternal Life in 1993. Merged with Catholic Knights on April 1, 2010, into Catholic Financial Life. Catholic Fraternal League - Originally incorporated in Massachusetts on June 19, 1889, as the International Fraternal Alliance.
Sources: en.wikipedia.org
Flucloxacillin, also known as floxacillin, is an antibiotic used to treat mastitis, skin infections, external ear infections, infections of leg ulcers, diabetic foot infections, and bone infections. It may be used together with other medications to treat pneumonia, and endocarditis. It may also be used prior to surgery to prevent Staphylococcus infections. It is not effective against methicillin-resistant Staphylococcus aureus (MRSA). It is taken by mouth or given by injection into a vein or muscle. Common side effects include an upset stomach. Other side effects may include muscle or joint pains, shortness of breath, and liver problems. It appears to be safe during pregnancy and breastfeeding. It should not be used in those who are allergic to penicillin. It is a narrow-spectrum beta-lactam antibiotic of the penicillin class. It is similar in effect to cloxacillin and dicloxacillin, being active against penicillinase forming bacteria. Flucloxacillin was patented in 1961. Flucloxacillin is not available in the United States.
=== History of mid to large scale oligonucleotide synthesis === Large scale oligonucleotide synthesizers were often developed by augmenting the capabilities of a preexisting instrument platform. One of the first mid scale synthesizers appeared in the late 1980s, manufactured by the Biosearch company in Novato, CA (The 8800). This platform was originally designed as a peptide synthesizer and made use of a fluidized bed reactor essential for accommodating the swelling characteristics of polystyrene supports used in the Merrifield methodology. Oligonucleotide synthesis involved the use of CPG (controlled pore glass) which is a rigid support and is more suited for column reactors as described above. The scale of the 8800 was limited to the flow rate required to fluidize the support. Some novel reactor designs as well as higher than normal pressures enabled the 8800 to achieve scales that would prepare 1 mmol of oligonucleotide. In the mid 1990s several companies developed platforms that were based on semi-preparative and preparative liquid chromatographs. These systems were well suited for a column reactor approach. In most cases all that was required was to augment the number of fluids that could be delivered to the column. Oligo synthesis requires a minimum of 10 and liquid chromatographs usually accommodate 4. This was an easy design task and some semi-automatic strategies worked without any modifications to the preexisting LC equipment. PerSeptive Biosystems as well as Pharmacia (GE) were two of several companies that developed synthesizers out of liquid chromatographs.
The authors concluded that the effects previously attributed to oxazepam were instead likely caused by a combination of fish being stressed by human handling and small aquaria, followed by being exposed to a novel environment.
Onyx Pharmaceuticals, Inc. was a pharmaceutical company headquartered in South San Francisco, California that developed and marketed cancer treatment medications. It was founded and incorporated with the California Secretary of State in February 1992 by venture capitalist Kevin J. Kinsella and Frank McCormick, Ph.D., FRS, D.Sc. (Hon.), a renowned British-American biochemist. McCormick served as the chief scientific officer until 1996, while Kinsella chaired the company's board of directors. On March 26, 1996, Onyx withdrew its corporate registration with the California Secretary of State and reincorporated in the state of Delaware in advance of successfully taking the company public on the NASDAQ exchange using National Market symbol ONXX on May 9, 1996. In 2009, the company acquired private biotechnology company Proteolix for US$276 million in cash plus additional milestone payments. In January 2012, the company was named "the top biotechnology takeover target in 2012" in an industry survey conducted by the ISI Group. Onyx president and CEO N. Anthony Coles had said that Onyx liked its prospects as an independent company and was focused on bringing new therapies to patients. However, by the end of August 2013, Amgen announced that it was acquiring Onyx in an agreed US$10.4 billion deal.
Sources: en.wikipedia.org
It activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. This dual activity separates it from agents that act on only one of the two receptors. The relative contribution of each receptor to clinical effects remains an open area of study.
United States approval for type 2 diabetes was granted in 2022, and a chronic weight management indication was added later. Approval timelines differ across other jurisdictions. Earlier human data came from phase 1 and phase 2 trials published before those decisions.
Native hormones are short-lived peptides that enzymes degrade within minutes. Tirzepatide carries non-natural residues and a fatty acid chain that resist this breakdown and extend circulation time. The result is a longer interval between administrations than the natural hormones could support.
Solid material is normally kept frozen at about -20 degrees Celsius, desiccated and protected from light. Solutions are held cold and used within a defined window because degradation products accumulate over time.